Announcements Trials
Browse Landscape Eligibility

Clinical Trials

4 trials
RecentStart dateEnrollment
CYH33 × Clear all

Phase

Phase 1 3Phase 2 1

Status

Unknown 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Breast 2Other solid neoplasm 1Genitourinary 1

Conditions

Ovarian Neoplasms 2Recurrence 1Prostatic Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 2848Cisplatin 2837Carboplatin 2635Radiotherapy 2522Paclitaxel 2424Gemcitabine 2263pembrolizumab 2099Docetaxel 1978Bevacizumab 1966Fluorouracil 1660Capecitabine 1640Oxaliplatin 1551Dexamethasone 1417Nivolumab 1394Doxorubicin 1349Rituximab 1338Magnetic Resonance Spectroscopy 1229Etoposide 1198Irinotecan 1122Leucovorin 1096Drug Therapy 1062Cytarabine 1010Pemetrexed 944fludarabine 933Specimen Handling 875Vincristine 857Prednisone 851Lenalidomide 838Trastuzumab 837Cetuximab 831

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT05043922 2026-01-30

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Haihe Biopharma Co., Ltd.

Phase 2 Active not recruiting
93 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03544905 2025-04-22

Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33

Haihe Biopharma Co., Ltd.

Phase 1 Completed
206 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Haihe Biopharma Co., Ltd.

Phase 1 Terminated
24 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT04856371 2021-04-23

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Haihe Biopharma Co., Ltd.

Phase 1 Unknown
228 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡